These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12400584)

  • 41. [Action of Poly-Karaya in functional colopathies. Results of a multicenter study of 114 patients].
    Dorf G; Licht H; Namias A; Paraf A
    Med Chir Dig; 1981; 10(6):533-8. PubMed ID: 7311642
    [No Abstract]   [Full Text] [Related]  

  • 42. Review article: tegaserod -- the global experience.
    Chey WD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():15-9. PubMed ID: 15521850
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Irritable bowel syndrome(IBS)].
    Kawasaki Y; Fujita K
    Ryoikibetsu Shokogun Shirizu; 2003; (38):559-62. PubMed ID: 12877049
    [No Abstract]   [Full Text] [Related]  

  • 44. The FDA's decision-making process: isn't it time to temper the principle of protective paternalism?
    Brandt LJ
    Am J Gastroenterol; 2008 May; 103(5):1226-7. PubMed ID: 18477347
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tegaserod for chronic constipation.
    Brown SR
    J Fam Pract; 2005 Dec; 54(12):1060, 1063. PubMed ID: 16370097
    [No Abstract]   [Full Text] [Related]  

  • 46. Tegaserod in patients with irritable bowel syndrome.
    Schooff M; Stelter C
    Am Fam Physician; 2004 Dec; 70(11):2107-8. PubMed ID: 15606056
    [No Abstract]   [Full Text] [Related]  

  • 47. [Irritable colon].
    Lindberg M
    Ugeskr Laeger; 2001 Oct; 163(41):5694. PubMed ID: 11665483
    [No Abstract]   [Full Text] [Related]  

  • 48. Alosetron: a case study in regulatory capture, or a victory for patients' rights?
    Moynihan R
    BMJ; 2002 Sep; 325(7364):592-5. PubMed ID: 12228140
    [No Abstract]   [Full Text] [Related]  

  • 49. Recognition and treatment of irritable bowel syndrome among women with chronic pelvic pain.
    Williams RE; Hartmann KE; Sandler RS; Miller WC; Savitz LA; Steege JF
    Am J Obstet Gynecol; 2005 Mar; 192(3):761-7. PubMed ID: 15746669
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical inquiries: what is the role of prokinetic agents for constipation?
    Boyle G; Mounsey A; Crowell K
    J Fam Pract; 2009 Apr; 58(4):220d-220f. PubMed ID: 19358794
    [No Abstract]   [Full Text] [Related]  

  • 51. Combination drugs in gastroenterology.
    Connell AM
    Am J Gastroenterol; 1986 May; 81(5):392-6. PubMed ID: 3706256
    [No Abstract]   [Full Text] [Related]  

  • 52. Effectiveness of tegaserod therapy on GI-related resource utilization in a managed care population.
    Stephenson JJ; Barghout V; Kahler KH; Fernandes J; Beaulieu JF; Joo S; Boccuzzi SJ
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S35-42. PubMed ID: 15926762
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Irritable bowel syndrome. 10% to 20% of older adults have symptoms consistent with diagnosis.
    Ehrenpreis ED
    Geriatrics; 2005 Jan; 60(1):25-8. PubMed ID: 15700946
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A response to Farup and Bytzer. Tegaserod Nordic trial.
    Nyhlin H; Hunt R
    Scand J Gastroenterol; 2004 Aug; 39(8):803-4. PubMed ID: 15513374
    [No Abstract]   [Full Text] [Related]  

  • 55. Motility disorders. Abnormal gastrointestinal muscle contractions.
    Mayo Clin Health Lett; 2004 Apr; 22(4):6. PubMed ID: 15101342
    [No Abstract]   [Full Text] [Related]  

  • 56. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity.
    Rodriguez-Stanley S; Zubaidi S; Proskin HM; Kralstein JR; Shetzline MA; Miner PB
    Clin Gastroenterol Hepatol; 2006 Apr; 4(4):442-50. PubMed ID: 16616348
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease.
    Sullivan KL; Staffetti JF; Hauser RA; Dunne PB; Zesiewicz TA
    Mov Disord; 2006 Jan; 21(1):115-6. PubMed ID: 16142776
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.
    Schiller LR; Johnson DA
    Am J Gastroenterol; 2008 Apr; 103(4):815-9. PubMed ID: 18397418
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation.
    Di Palma JA; Cleveland MV; McGowan J; Herrera JL
    Am J Gastroenterol; 2007 Sep; 102(9):1964-71. PubMed ID: 17573794
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Do antibiotics influence IBS?
    Pimentel M
    Am J Gastroenterol; 2002 Oct; 97(10):2681. PubMed ID: 12385465
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.